LaVerne A. Mooney
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
LaVerne A. Mooney has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Rundle
Department of Epidemiology, Mailman School of Public Health, Columbia University
6 shared publications Deliang Tang
Department of Environmental Health Sciences, Columbia Center for Children's Environmental Health, Mailman School of Public Health of Columbia University, New York, New York and
4 shared publicationsFrederica Perera
Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, USA
3 shared publications- Ann Madsen
New York City Department of Health and Mental Hygiene
2 shared publications Bernadette A. Mansi
2 shared publicationsBernadette Mansi
B Publications & Disclosure Practices , GlaxoSmithKline , Collegeville , PA , USA
2 shared publications
Latest Publications
- Open Access
- 19 February 2019
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 35 (7) , 1221-1230
Transparency and credibility of industry-sponsored clinical trial publications: a survey of journal editors
Objective: To examine how medical journal editors perceive changes in transparency and credibility of industry-sponsored clinical trial publications over a 5-year period (2010 to 2015). Methods: From July to September 2015, a survey link was e-mailed to journal editors identified from the Thomson Reuters registry. Editors ranked their perception of a) change in transparency and credibility of industry-sponsored clinical trial publications; b) 8 ‘Publication Best Practices’ and the impact of each on transparency; and c) the importance and adoption of the previously published “10 Recommendations for Closing the Credibility Gap in Reporting Industry-Sponsored Clinical Research”. Results: Of 510 editors who opened the survey, a total of 293 editors comprised the analysis pool. Majority of respondents reported their location as the US (46%) or EU (45%) and most commonly reported editorial titles were deputy/assistant editor (36%), editor-in-chief (35%), and section editor (24%). More editors reported improved versus worsened transparency (63.5% vs 6.1%) and credibility (53.2% vs 10.4%). Best practices that contributed most to improved transparency were ‘disclosure of the study sponsor’ and ‘registration and posting of trial results.’ Respondents ranked the importance of 9 recommendations as moderate or extremely important, and adoption of all recommendations was ranked minimal to moderate. Conclusions: The 293 editors who responded perceived an improvement in transparency and credibility of industry-sponsored publications from 2010 to 2015. Confirmation of the importance of 9/10 recommendations by the respondents was encouraging. Yet, low adoption rates suggest additional work is required by all stakeholders to improve best practices, transparency, and credibility.
- 19 February 2019
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 35 (7) , 1221-1230
Open AccessTransparency and credibility of industry-sponsored clinical trial publications: a survey of journal editors
Objective: To examine how medical journal editors perceive changes in transparency and credibility of industry-sponsored clinical trial publications over a 5-year period (2010 to 2015). Methods: From July to September 2015, a survey link was e-mailed to journal editors identified from the Thomson Reuters registry. Editors ranked their perception of a) change in transparency and credibility of industry-sponsored clinical trial publications; b) 8 ‘Publication Best Practices’ and the impact of each on transparency; and c) the importance and adoption of the previously published “10 Recommendations for Closing the Credibility Gap in Reporting Industry-Sponsored Clinical Research”. Results: Of 510 editors who opened the survey, a total of 293 editors comprised the analysis pool. Majority of respondents reported their location as the US (46%) or EU (45%) and most commonly reported editorial titles were deputy/assistant editor (36%), editor-in-chief (35%), and section editor (24%). More editors reported improved versus worsened transparency (63.5% vs 6.1%) and credibility (53.2% vs 10.4%). Best practices that contributed most to improved transparency were ‘disclosure of the study sponsor’ and ‘registration and posting of trial results.’ Respondents ranked the importance of 9 recommendations as moderate or extremely important, and adoption of all recommendations was ranked minimal to moderate. Conclusions: The 293 editors who responded perceived an improvement in transparency and credibility of industry-sponsored publications from 2010 to 2015. Confirmation of the importance of 9/10 recommendations by the respondents was encouraging. Yet, low adoption rates suggest additional work is required by all stakeholders to improve best practices, transparency, and credibility.
- Open Access
Cross-sectional study of Pfizer-sponsored clinical trials: assessment of time to publication and publication history
Objective To estimate the proportion of Pfizer-sponsored clinical trials that completed in 2010 and are published as manuscripts in the peer-reviewed literature, and to assess the manuscript development history. Design Retrospective, cross-sectional analysis. Setting Clinical trials registered in ClinicalTrials.gov that completed in 2010 for approved, Pfizer prescription products in patients or vaccines in healthy participants. Main outcome measures The proportion of studies for which the primary outcome(s) was published and the median time from study completion to publication. The manuscript development history included the number of times a manuscript was submitted before it was accepted for publication. Results Among registered clinical trials for which Pfizer was the sponsor that completed in 2010, 76 met all inclusion criteria. The primary outcome(s) for 65 (85%) studies was published in 71 manuscripts; the median time to publication was 31 months (range 3–63 months). Of the remaining 11 studies, 2 had been submitted to at least one journal, 2 had not yet been submitted and 7 had no plans to publish because the study had terminated early due to recruitment challenges. Manuscripts accepted at the first choice journal were published at median time of 28 months (range 8–63, n=31), those accepted at second choice journal were published at 32 months (3–45, n=19), and for those accepted at third choice journal, it was 40 months (range 24–53, n=13). Conclusions The publication rate and median time to publication from study completion for Pfizer-sponsored studies were comparable to those previously reported for combined analyses of industry and non-industry sectors. Opportunities exist for sponsors, authors and journals to explore ideas that would facilitate more timely publication for clinical trial results. However, to be effective, such changes may need to revisit the entire publication process.
Open AccessCross-sectional study of Pfizer-sponsored clinical trials: assessment of time to publication and publication history
Objective To estimate the proportion of Pfizer-sponsored clinical trials that completed in 2010 and are published as manuscripts in the peer-reviewed literature, and to assess the manuscript development history. Design Retrospective, cross-sectional analysis. Setting Clinical trials registered in ClinicalTrials.gov that completed in 2010 for approved, Pfizer prescription products in patients or vaccines in healthy participants. Main outcome measures The proportion of studies for which the primary outcome(s) was published and the median time from study completion to publication. The manuscript development history included the number of times a manuscript was submitted before it was accepted for publication. Results Among registered clinical trials for which Pfizer was the sponsor that completed in 2010, 76 met all inclusion criteria. The primary outcome(s) for 65 (85%) studies was published in 71 manuscripts; the median time to publication was 31 months (range 3–63 months). Of the remaining 11 studies, 2 had been submitted to at least one journal, 2 had not yet been submitted and 7 had no plans to publish because the study had terminated early due to recruitment challenges. Manuscripts accepted at the first choice journal were published at median time of 28 months (range 8–63, n=31), those accepted at second choice journal were published at 32 months (3–45, n=19), and for those accepted at third choice journal, it was 40 months (range 24–53, n=13). Conclusions The publication rate and median time to publication from study completion for Pfizer-sponsored studies were comparable to those previously reported for combined analyses of industry and non-industry sectors. Opportunities exist for sponsors, authors and journals to explore ideas that would facilitate more timely publication for clinical trial results. However, to be effective, such changes may need to revisit the entire publication process.
- Top Cited PapersOpen Access
- 15 September 2015
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 163 (6) , 461-464
Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3
This updated Good Publication Practice (GPP) guideline, known as GPP3, builds on earlier versions and provides recommendations for individuals and organizations that contribute to the publication of research results sponsored or supported by pharmaceutical, medical device, diagnostics, and biotechnology companies. The recommendations are designed to help individuals and organizations maintain ethical and transparent publication practices and comply with legal and regulatory requirements. These recommendations cover publications in peer-reviewed journals and presentations (oral or poster) at scientific congresses. The International Society for Medical Publication Professionals invited more than 3000 professionals worldwide to apply for a position on the steering committee, or as a reviewer, for this guideline. The GPP2 authors reviewed all applications (n = 241) and assembled an 18-member steering committee that represented 7 countries and a diversity of publication professions and institutions. From the 174 selected reviewers, 94 sent comments on the second draft, which steering committee members incorporated after discussion and consensus. The resulting guideline includes new sections (Principles of Good Publication Practice for Company-Sponsored Medical Research, Data Sharing, Studies That Should Be Published, and Plagiarism), expands guidance on the International Committee of Medical Journal Editors' authorship criteria and common authorship issues, improves clarity on appropriate author payment and reimbursement, and expands information on the role of medical writers. By following good publication practices (including GPP3), individuals and organizations will show integrity, accountability, and responsibility for accurate, complete, and transparent reporting in their publications and presentations.
- 15 September 2015
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 163 (6) , 461-464
Top Cited PapersOpen AccessGood Publication Practice for Communicating Company-Sponsored Medical Research: GPP3
This updated Good Publication Practice (GPP) guideline, known as GPP3, builds on earlier versions and provides recommendations for individuals and organizations that contribute to the publication of research results sponsored or supported by pharmaceutical, medical device, diagnostics, and biotechnology companies. The recommendations are designed to help individuals and organizations maintain ethical and transparent publication practices and comply with legal and regulatory requirements. These recommendations cover publications in peer-reviewed journals and presentations (oral or poster) at scientific congresses. The International Society for Medical Publication Professionals invited more than 3000 professionals worldwide to apply for a position on the steering committee, or as a reviewer, for this guideline. The GPP2 authors reviewed all applications (n = 241) and assembled an 18-member steering committee that represented 7 countries and a diversity of publication professions and institutions. From the 174 selected reviewers, 94 sent comments on the second draft, which steering committee members incorporated after discussion and consensus. The resulting guideline includes new sections (Principles of Good Publication Practice for Company-Sponsored Medical Research, Data Sharing, Studies That Should Be Published, and Plagiarism), expands guidance on the International Committee of Medical Journal Editors' authorship criteria and common authorship issues, improves clarity on appropriate author payment and reimbursement, and expands information on the role of medical writers. By following good publication practices (including GPP3), individuals and organizations will show integrity, accountability, and responsibility for accurate, complete, and transparent reporting in their publications and presentations.
- Open Access
- 24 October 2014
- Published by Springer Nature in BMC Medicine
- Vol. 12 (1) , 197
Five-step authorship framework to improve transparency in disclosing contributors to industry-sponsored clinical trial publications
Authorship guidelines have established criteria to guide author selection based on significance of contribution and helped to define associated responsibilities and accountabilities for the published findings. However, low awareness, variable interpretation, and inconsistent application of these guidelines can lead to confusion and a lack of transparency when recognizing those who merit authorship. This article describes a research project led by the Medical Publishing Insights and Practices (MPIP) Initiative to identify current challenges when determining authorship for industry-sponsored clinical trials and develop an improved approach to facilitate decision-making when recognizing authors from related publications. A total of 498 clinical investigators, journal editors, publication professionals and medical writers were surveyed to understand better how they would adjudicate challenging, real-world authorship case scenarios, determine the perceived frequency of each scenario and rate their confidence in the responses provided. Multiple rounds of discussions about these results with journal editors, clinical investigators and industry representatives led to the development of key recommendations intended to enhance transparency when determining authorship. These included forming a representative group to establish authorship criteria early in a trial, having all trial contributors agree to these criteria and documenting trial contributions to objectively determine who warrants an invitation to participate in the manuscript development process. The resulting Five-step Authorship Framework is designed to create a more standardized approach when determining authorship for clinical trial publications. Overall, these recommendations aim to facilitate more transparent authorship decisions and help readers better assess the credibility of results and perspectives of the authors for medical research more broadly. Please see related article: http://www.biomedcentral.com/1741-7015/12/214 .
- 24 October 2014
- Published by Springer Nature in BMC Medicine
- Vol. 12 (1) , 197
Open AccessFive-step authorship framework to improve transparency in disclosing contributors to industry-sponsored clinical trial publications
Authorship guidelines have established criteria to guide author selection based on significance of contribution and helped to define associated responsibilities and accountabilities for the published findings. However, low awareness, variable interpretation, and inconsistent application of these guidelines can lead to confusion and a lack of transparency when recognizing those who merit authorship. This article describes a research project led by the Medical Publishing Insights and Practices (MPIP) Initiative to identify current challenges when determining authorship for industry-sponsored clinical trials and develop an improved approach to facilitate decision-making when recognizing authors from related publications. A total of 498 clinical investigators, journal editors, publication professionals and medical writers were surveyed to understand better how they would adjudicate challenging, real-world authorship case scenarios, determine the perceived frequency of each scenario and rate their confidence in the responses provided. Multiple rounds of discussions about these results with journal editors, clinical investigators and industry representatives led to the development of key recommendations intended to enhance transparency when determining authorship. These included forming a representative group to establish authorship criteria early in a trial, having all trial contributors agree to these criteria and documenting trial contributions to objectively determine who warrants an invitation to participate in the manuscript development process. The resulting Five-step Authorship Framework is designed to create a more standardized approach when determining authorship for clinical trial publications. Overall, these recommendations aim to facilitate more transparent authorship decisions and help readers better assess the credibility of results and perspectives of the authors for medical research more broadly. Please see related article: http://www.biomedcentral.com/1741-7015/12/214 .
- 4 May 2012
- Published by SciVee, Inc
Ten Recommendations for Closing the Credibility Gap in Reporting
- Open Access
- 1 May 2012
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 87 (5) , 424-429
Ten Recommendations for Closing the Credibility Gap in Reporting Industry-Sponsored Clinical Research: A Joint Journal and Pharmaceutical Industry Perspective
- 1 May 2012
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 87 (5) , 424-429
Open AccessTen Recommendations for Closing the Credibility Gap in Reporting Industry-Sponsored Clinical Research: A Joint Journal and Pharmaceutical Industry Perspective
- 19 May 2010
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 26 (8) , 1967-1982
Authors' Submission Toolkit: A practical guide to getting your research published
(2010). Authors' Submission Toolkit: A practical guide to getting your research published. Current Medical Research and Opinion: Vol. 26, No. 8, pp. 1967-1982. doi: 10.1185/03007995.2010.499344
- 19 May 2010
- Published by Informa Healthcare in Current Medical Research and Opinion
- Vol. 26 (8) , 1967-1982
Authors' Submission Toolkit: A practical guide to getting your research published
(2010). Authors' Submission Toolkit: A practical guide to getting your research published. Current Medical Research and Opinion: Vol. 26, No. 8, pp. 1967-1982. doi: 10.1185/03007995.2010.499344
- Open Access
- 7 May 2010
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 64 (8) , 1028-1033
Enhancing transparency and efficiency in reporting industry-sponsored clinical research: report from the Medical Publishing Insights and Practices initiative
- 7 May 2010
- Published by Hindawi Limited in International Journal Of Clinical Practice
- Vol. 64 (8) , 1028-1033
Open AccessEnhancing transparency and efficiency in reporting industry-sponsored clinical research: report from the Medical Publishing Insights and Practices initiative
- 27 July 2007
- Published by Springer Nature in Journal of Urban Health
- Vol. 84 (5) , 722-732
Traditional Physical Activity Indexes Derived from the Harvard Alumni Activity Survey Have Low Construct Validity in a Lower Income, Urban Population
The purpose of this study is to investigate the construct validity of the Harvard Alumni Activity Survey (HAAS) in an urban, lower income population. Data were collected from 192 smokers enrolled in an antioxidant micronutrient trial. Activity data were compared to body mass index (BMI), diastolic, and systolic blood pressure. The traditional physical activity index (PAI), using data on stair climbing, walking, and sports, was calculated including and excluding body mass. A new scale, the total weekly activity (TWA) scale, was derived from other questions on the HAAS. The PAI scale calculated with body mass was unassociated with BMI and blood pressure. The PAI scale calculated without body mass was unassociated with BMI and systolic blood pressure but was associated with diastolic blood pressure (Beta = −0.001, p = 0.03). The TWA scale was associated with BMI (Beta = −0.01, p = 0.01), diastolic (Beta = −0.03, p = 0.01), and systolic blood pressure (Beta = −0.04, p = 0.01). A one standard deviation change in the TWA scale is predicted to be equivalent to a change of 0.99 BMI units, 2.97 mmHg of diastolic blood pressure, and 3.96 mmHg of systolic blood pressure. This work suggests that the TWA scale has greater construct validity than the traditional PAI scale in this population.
- 27 July 2007
- Published by Springer Nature in Journal of Urban Health
- Vol. 84 (5) , 722-732
Traditional Physical Activity Indexes Derived from the Harvard Alumni Activity Survey Have Low Construct Validity in a Lower Income, Urban Population
The purpose of this study is to investigate the construct validity of the Harvard Alumni Activity Survey (HAAS) in an urban, lower income population. Data were collected from 192 smokers enrolled in an antioxidant micronutrient trial. Activity data were compared to body mass index (BMI), diastolic, and systolic blood pressure. The traditional physical activity index (PAI), using data on stair climbing, walking, and sports, was calculated including and excluding body mass. A new scale, the total weekly activity (TWA) scale, was derived from other questions on the HAAS. The PAI scale calculated with body mass was unassociated with BMI and blood pressure. The PAI scale calculated without body mass was unassociated with BMI and systolic blood pressure but was associated with diastolic blood pressure (Beta = −0.001, p = 0.03). The TWA scale was associated with BMI (Beta = −0.01, p = 0.01), diastolic (Beta = −0.03, p = 0.01), and systolic blood pressure (Beta = −0.04, p = 0.01). A one standard deviation change in the TWA scale is predicted to be equivalent to a change of 0.99 BMI units, 2.97 mmHg of diastolic blood pressure, and 3.96 mmHg of systolic blood pressure. This work suggests that the TWA scale has greater construct validity than the traditional PAI scale in this population.
- 1 January 2007
- Published by Taylor & Francis in Biomarkers
- Vol. 12 (2) , 123-132
The association between benzo[a]pyrene-DNA adducts and body mass index, calorie intake and physical activity
Prior work suggests that body size and fat content may influence carcinogen-DNA adduct levels measured in white blood cells. Here we consider energy balance more broadly by assessing the impact of body mass index (BMI), physical activity and calorie intake on the presence of benzo[a]pyrene-DNA (BP-DNA) adducts in white blood cell DNA. Our cross-sectional study employed subjects from a separately conducted intervention trial. Physical activity and food intake data were collected at 12 and 15 months of follow-up, respectively. BP-DNA adducts were measured by high-performance liquid chromatography (HPLC) in white blood cell samples collected at 12 months of follow-up. Complete data on all variables were available from 143 subjects. Logistic regression showed that BMI was inversely associated with the presence of detectable adducts (OR = 0.90, p = 0.02), and that hours of moderate-intensity physical activity were positively associated with the presence of detectable adducts (OR = 1.04, p = 0.04). These results provide further evidence that body fat content influences carcinogen-DNA adduct levels, probably by altering the distribution of the lipophilic parent compound.
- 1 January 2007
- Published by Taylor & Francis in Biomarkers
- Vol. 12 (2) , 123-132
The association between benzo[a]pyrene-DNA adducts and body mass index, calorie intake and physical activity
Prior work suggests that body size and fat content may influence carcinogen-DNA adduct levels measured in white blood cells. Here we consider energy balance more broadly by assessing the impact of body mass index (BMI), physical activity and calorie intake on the presence of benzo[a]pyrene-DNA (BP-DNA) adducts in white blood cell DNA. Our cross-sectional study employed subjects from a separately conducted intervention trial. Physical activity and food intake data were collected at 12 and 15 months of follow-up, respectively. BP-DNA adducts were measured by high-performance liquid chromatography (HPLC) in white blood cell samples collected at 12 months of follow-up. Complete data on all variables were available from 143 subjects. Logistic regression showed that BMI was inversely associated with the presence of detectable adducts (OR = 0.90, p = 0.02), and that hours of moderate-intensity physical activity were positively associated with the presence of detectable adducts (OR = 1.04, p = 0.04). These results provide further evidence that body fat content influences carcinogen-DNA adduct levels, probably by altering the distribution of the lipophilic parent compound.